Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Ordinary Shares, no par value and American Depositary Shares, each representing three hundred Ordinary Shares, no par value
-
Shares outstanding
-
3,543,587,624
-
Total 13F shares
-
339,690
-
Share change
-
-3,225
-
Total reported value
-
$1,576,875
-
Price per share
-
$4.64
-
Number of holders
-
5
-
Value change
-
-$15,543
-
Number of buys
-
2
-
Number of sells
-
1
Institutional Holders of Radiopharm Theranostics Ltd - Ordinary Shares, no par value and American Depositary Shares, each representing three hundred Ordinary Shares, no par value (RADX) as of Q2 2025
As of 30 Jun 2025,
Radiopharm Theranostics Ltd - Ordinary Shares, no par value and American Depositary Shares, each representing three hundred Ordinary Shares, no par value (RADX) was held by
5 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
339,690 shares.
The largest 5 holders included
SILVERARC CAPITAL MANAGEMENT, LLC, Regal Partners Ltd, Affinity Asset Advisors, LLC, UBS Group AG, and PNC Financial Services Group, Inc..
This page lists
5
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.